Amphastar Pharmaceuticals (AMPH) EBITDA Margin: History & Chart

Amphastar Pharmaceuticals, Inc.(AMPH)

Drug Manufacturers - Specialty & Generic · Rancho Cucamonga, CA

$25.13-0.24 (-0.95%)

Delayed quote: Oct 6, 2026, 10:35 AM EDT

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Rancho Cucamonga, CA

1,976 employees

www.amphastar.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Yongfeng Zhang

View full financials

AMPH EBITDA Margin Metrics

EBITDA MARGIN

28.28%

EBITDA MARGIN AVG TTM

26.31%

EBITDA MARGIN AVG 3Y

33.73%

EBITDA MARGIN AVG 5Y

29.12%

EBITDA MARGIN AVG 10Y

19.01%

EBITDA MARGIN AVG 15Y

N/A

EBITDA MARGIN AVG 20Y

N/A

CURRENT VS TTM AVG

+7.48%

CURRENT VS 3Y AVG

-16.15%

CURRENT VS 5Y AVG

-2.88%

CURRENT VS 10Y AVG

+48.74%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Amphastar Pharmaceuticals, Inc. (AMPH)	$1.11B	28.28%	26.31%	33.73%	29.12%
Harrow Health, Inc. (HROW)vs ›	$1.12B	21.12%	16.04%	11.58%	9.26%
Bicara Therapeutics Inc. Common Stock (BCAX)vs ›	$1.09B	N/A	N/A	N/A	N/A
IRadimed Corporation (IRMD)vs ›	$1.09B	34.04%	32.58%	31.87%	26.02%
Damora Therapeutics, Inc. (DMRA)vs ›	$1.13B	N/A	N/A	N/A	N/A
Kardigan, Inc. (KARD)vs ›	$1.12B	N/A	N/A	N/A	N/A
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.14B	N/A	N/A	N/A	N/A
GoodRx Holdings, Inc. (GDRX)vs ›	$1.16B	21.67%	19.38%	14.20%	2.75%
Castle Biosciences, Inc. (CSTL)vs ›	$1.05B	-0.59%	3.42%	-15.99%	-18.77%
Teladoc Health, Inc. (TDOC)vs ›	$1.05B	3.96%	-13.21%	-146.19%	-104.68%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Amphastar Pharmaceuticals, Inc. (AMPH)

$1.11B

28.28%

26.31%

33.73%

29.12%

Harrow Health, Inc. (HROW)vs ›

$1.12B

21.12%

16.04%

11.58%

9.26%

Bicara Therapeutics Inc. Common Stock (BCAX)vs ›

$1.09B

N/A

IRadimed Corporation (IRMD)vs ›

$1.09B

34.04%

32.58%

31.87%

26.02%

Damora Therapeutics, Inc. (DMRA)vs ›

$1.13B

N/A

Kardigan, Inc. (KARD)vs ›

$1.12B

N/A

Avalyn Pharma Inc. Common Stock (AVLN)vs ›

$1.14B

N/A

GoodRx Holdings, Inc. (GDRX)vs ›

$1.16B

21.67%

19.38%

14.20%

2.75%

Castle Biosciences, Inc. (CSTL)vs ›

$1.05B

-0.59%

3.42%

-15.99%

-18.77%

Teladoc Health, Inc. (TDOC)vs ›

$1.05B

3.96%

-13.21%

-146.19%

-104.68%

EBITDA Margin FAQ

What is the EBITDA margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The EBITDA margin for AMPH stock is 28.28%.

Is Amphastar Pharmaceuticals, Inc.'s EBITDA margin high or low?

The EBITDA margin of 28.28% is in line with its 5-year average of 29.12%, around the middle of its 5-year range (17.14%–47.77%).

What is the TTM average EBITDA margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The TTM average EBITDA margin for AMPH stock is 26.31%.

What is the 3Y average EBITDA margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 3Y average EBITDA margin for AMPH stock is 33.73%.

What is the 5Y average EBITDA margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 5Y average EBITDA margin for AMPH stock is 29.12%.

What is the 10Y average EBITDA margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 10Y average EBITDA margin for AMPH stock is 19.01%.

DATE	EBITDA MARGIN
2026-06-30	31.72%
2026-03-31	17.60%
2025-12-31	28.18%
2025-09-30	20.56%
2025-06-30	33.50%
2025-03-31	30.79%
2024-12-31	32.06%
2024-09-30	37.86%
2024-06-30	38.03%
2024-03-31	36.07%
2023-12-31	38.05%
2023-09-30	47.77%
2023-06-30	30.14%
2023-03-31	29.16%
2022-12-31	33.52%
2022-09-30	25.43%
2022-06-30	25.64%
2022-03-31	23.60%
2021-12-31	25.48%
2021-09-30	27.88%
2021-06-30	17.14%
2021-03-31	16.63%
2020-12-31	10.06%
2020-09-30	12.21%
2020-06-30	3.49%
2020-03-31	15.71%
2019-12-31	6.46%
2019-09-30	9.57%
2019-06-30	8.45%
2019-03-31	1.69%
2018-12-31	6.61%
2018-09-30	8.82%
2018-06-30	1.74%
2018-03-31	-10.25%
2017-12-31	3.74%
2017-09-30	1.79%
2017-06-30	9.24%
2017-03-31	9.22%
2016-12-31	-1.11%
2016-09-30	14.81%
2016-06-30	20.50%
2016-03-31	12.64%
2015-12-31	22.95%
2015-09-30	-0.60%
2015-06-30	-12.81%
2015-03-31	-7.05%
2014-12-31	-5.81%
2014-09-30	-6.93%
2014-06-30	4.91%
2014-03-31	3.15%
2013-12-31	11.65%
2013-09-30	5.89%
2013-06-30	24.45%
2013-03-31	10.18%
2012-12-31	18.46%

DATE

EBITDA MARGIN

2026-06-30

31.72%

2026-03-31

17.60%

2025-12-31

28.18%

2025-09-30

20.56%

2025-06-30

33.50%

2025-03-31

30.79%

2024-12-31

32.06%

2024-09-30

37.86%

2024-06-30

38.03%

2024-03-31

36.07%

2023-12-31

38.05%

2023-09-30

47.77%

2023-06-30

30.14%

2023-03-31

29.16%

2022-12-31

33.52%

2022-09-30

25.43%

2022-06-30

25.64%

2022-03-31

23.60%

2021-12-31

25.48%

2021-09-30

27.88%

2021-06-30

17.14%

2021-03-31

16.63%

2020-12-31

10.06%

2020-09-30

12.21%

2020-06-30

3.49%

2020-03-31

15.71%

2019-12-31

6.46%

2019-09-30

9.57%

2019-06-30

8.45%

2019-03-31

1.69%

2018-12-31

6.61%

2018-09-30

8.82%

2018-06-30

1.74%

2018-03-31

-10.25%

2017-12-31

3.74%

2017-09-30

1.79%

2017-06-30

9.24%

2017-03-31

9.22%

2016-12-31

-1.11%

2016-09-30

14.81%

2016-06-30

20.50%

2016-03-31

12.64%

2015-12-31

22.95%

2015-09-30

-0.60%

2015-06-30

-12.81%

2015-03-31

-7.05%

2014-12-31

-5.81%

2014-09-30

-6.93%

2014-06-30

4.91%

2014-03-31

3.15%

2013-12-31

11.65%

2013-09-30

5.89%

2013-06-30

24.45%

2013-03-31

10.18%

2012-12-31

18.46%

EBITDA Margin: 28.28%

AMPH EBITDA Margin

AMPH Average EBITDA Margin Chart

AMPH Current vs Average EBITDA Margin Chart

AMPH EBITDA Margin Metrics

AMPH Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

AMPH EBITDA Margin History

Related Metrics